- Conditions
- Smallpox
- Interventions
- TPOXX, TPOXX Placebo
- Drug · Other
- Lead sponsor
- SIGA Technologies
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 467 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 9
- States / cities
- Miami, Florida • Orlando, Florida • Omaha, Nebraska + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 327
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostatic Neoplasms
- Interventions
- Not applicable for study
- Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 65 Years and older · Male only
- Enrollment
- 2,234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine, Rituximab, Truxima, Ruxience, Riabni
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 4
- States / cities
- Springdale, Arkansas • Clermont, Florida • Hattiesburg, Mississippi + 1 more
- Conditions
- Overactive Bladder
- Interventions
- botulinum toxin Type A, Normal Saline (Placebo)
- Biological · Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Infraorbital Hollowing
- Interventions
- JUVÉDERM VOLBELLA® XC injectable gel
- Device
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 15
- States / cities
- Beverly Hills, California • Newport Beach, California • San Diego, California + 11 more
- Conditions
- Longitudinal Studies, Prospective Studies, Biomarkers, Predictive Value of Tests, Telemedicine, Time of Death, Time Perception, Time Reaction, Time Efficiency, Time Management, Population, Population Groups, Epidemic Disease, Pandemic, Sex Behavior, Sex Characteristics, Sex Hormone, Cardio-pulmonary, Surgical, Drugs of Abuse, Health Risks, Clinical Outcomes
- Interventions
- No Study-Assigned Intervention
- Other
- Lead sponsor
- Truway Health, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2076
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 16
- States / cities
- Duarte, California • La Jolla, California • Long Beach, California + 10 more
- Conditions
- Myeloma
- Interventions
- Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
- Drug · Other
- Lead sponsor
- Robert Redner, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 22
- States / cities
- Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
- Conditions
- Macular Edema, Branch Retinal Vein Occlusion
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 553 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
- Conditions
- Rheumatoid Arthritis (RA), Arthritis, Rheumatoid (RA)
- Interventions
- PREVAIL model of care
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
- Interventions
- simlukafusp alfa, Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Gemcitabine, Vinorelbine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- San Francisco, California • Newnan, Georgia
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more
- Conditions
- Diabetic Macular Edema
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more
- Conditions
- Cancer, Dermatologic Conditions
- Interventions
- Quality of Life (QoL) Assessment
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 839 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 4
- States / cities
- Basking Ridge, New Jersey • East White Plains, New York • Hauppauge, New York + 1 more
- Conditions
- Myeloma, Endometrial Cancer
- Interventions
- BF4
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- MUC1 Dendritic Cell Vaccine (Cvac)
- Biological
- Lead sponsor
- Prima BioMed Ltd
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Greenbrae, California • La Jolla, California • Boca Raton, Florida + 2 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- PedAL BCU, LLC
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 133 more
- Conditions
- Dementia, Alzheimer Disease
- Interventions
- Brain Health Assessment
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 1,261 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- San Francisco, California
- Conditions
- Alopecia Areata, Alopecia Universalis, Alopecia Totalis
- Interventions
- ATI 502 0.46% Topical Solution
- Drug
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 20
- States / cities
- Rogers, Arkansas • Denver, Colorado • Boynton Beach, Florida + 17 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, t:slim X2 with Basal-IQ & Dexcom G6 CGM
- Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 7
- States / cities
- Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more
- Conditions
- Hypertension, Hyperlipidemias
- Interventions
- Penn Med Healthy Heart Program
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 1,980 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Development, Child, Adherence, Patient, Congenital Heart Disease
- Interventions
- Babysparks Application, pre and post-test Redcap Survey
- Device · Other
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- Up to 18 Months
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Bipolar I Disorder
- Interventions
- LB-102, Placebo
- Drug · Other
- Lead sponsor
- LB Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 26
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 23 more
- Conditions
- Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
- Interventions
- mRNA-2752, Durvalumab
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 16
- States / cities
- San Francisco, California • Santa Monica, California • Aurora, Colorado + 10 more